Nasdaq-listed Propan Biopharma has made a bold move into the cryptocurrency world with a planned investment of $100 million in Ethereum (ETH) over the next 12 months. This unprecedented decision by the company signals a growing trend of traditional financial institutions integrating digital assets into their core strategies. Propan Biopharma’s CEO, James Nathanielsz, highlighted the reasons behind this significant investment, emphasizing Ethereum’s superior speed and energy efficiency compared to Bitcoin. Nathanielsz explained that Ethereum’s transition to proof-of-stake (PoS) has made it a more sustainable choice for businesses with evolving sustainability goals.